Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CO5-R52H4 | Rabbit | Rabbit Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
|
CO5-H52H7 | Human | Human Complement C5 (w917s) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CO5-H52Hx | Human | Human Complement C5 (R885H) Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CO5-C52Hx | Cynomolgus | Cynomolgus Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CO5-R52H5 | Rat | Rat Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CO5-M52H4 | Mouse | Mouse Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CO5-H52Ha | Human | Human Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Eculizumab | 5G1-1; HAL-1; LEX-98; h-5G1.1 | Approved | Alexion Pharmaceuticals Inc | Soliris | Mainland China | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | s:18:"Alexion Europe Sas"; | 2007-03-16 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Delayed Graft Function; Neuromyelitis Optica; Asthma | Details |
Ravulizumab | ALXN-1210; ALXN-1810 | Approved | Alexion Pharmaceuticals Inc | Ultomiris | EU | Hemoglobinuria, Paroxysmal | s:18:"Alexion Europe Sas"; | 2018-12-21 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Atypical Hemolytic Uremic Syndrome; Thrombotic Microangiopathies; Lupus Nephritis; Pneumonia, Viral; Neuromyelitis Optica; Amyotrophic Lateral Sclerosis; Acute Lung Injury | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details | |
Tesidolumab | NOV-4; LFG-316 | Phase 2 Clinical | Novartis Pharma Ag, Morphosys Ag | Hemoglobinuria, Paroxysmal; Wet Macular Degeneration; Geographic Atrophy; Macular Degeneration | Details |
Eculizumab biosimilar (Samsung Bioepis) | SB-12 | Phase 3 Clinical | Samsung Bioepis | Hemoglobinuria, Paroxysmal | Details |
Nomacopan | EV-576; rVA576; rEV-576 | Phase 3 Clinical | Evolutec | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Arthritis, Rheumatoid; Sjogren's Syndrome; Autoimmune Diseases; Atypical Hemolytic Uremic Syndrome; Hemolytic-Uremic Syndrome; Asthma; Keratoconjunctivitis; Inflammation; Guillain-Barre Syndrome | Details |
Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
Pozelimab | REGN-3918 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
Eculizumab biosimilar (Amgen) | ABP-959 | Phase 3 Clinical | Amgen Inc | Hemoglobinuria, Paroxysmal; Hemolytic-Uremic Syndrome | Details |
Zilucoplan | RA-101495; RA-101495-SC | Phase 3 Clinical | Ra Pharma | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Lupus Nephritis; Hemolytic-Uremic Syndrome | Details |
Cemdisiran | ALN-CC5 | Phase 2 Clinical | Alnylam Pharmaceuticals Inc | Glomerulonephritis, IGA; Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Hemolytic-Uremic Syndrome | Details |
Crovalimab | SKY-59; RG-6107; CH-7092230; RO-7092230; RO-7112689; RO-7112689/F01 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd | Hemoglobinuria, Paroxysmal | Details |
Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | Biocad | Hemoglobinuria, Paroxysmal | Details |
BDB-001 | BDB-001; BDB001; BDB 001 | Phase 3 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19); Neoplasms; Hidradenitis Suppurativa | Details |
Vilobelimab | IFX-1; CaCP-29 | Phase 3 Clinical | Beijing Mabworks Biotech Co Ltd, Inflarx | Shock, Septic; Granulomatosis with Polyangiitis; Pyoderma Gangrenosum; Microscopic Polyangiitis; Sepsis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa; Systemic Inflammatory Response Syndrome | Details |
Avacincaptad pegol | ARC-187; ARC-1905 | Phase 3 Clinical | Archemix | Geographic Atrophy; Stargardt Disease; Macular Degeneration | Details |
Olendalizumab | ALXN-1007 | Phase 2 Clinical | Alexion Pharmaceuticals Inc | Graft vs Host Disease; Antiphospholipid Syndrome; Rejection of organ transplantation; Inflammation | Details |
ALXN-1720 | ALXN-1720 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Details |
This web search service is supported by Google Inc.